Alternative for anti-TNF antibodies for arthritis treatment

Molecular Therapy

Volumn 19, Issue 10, 2011, Pages 1887-1895

  Paquet, Joseph ^a   Henrionnet, Christel ^a   Pinzano, Astrid ^a   Vincourt, Jean Baptiste ^a   Gillet, Pierre ^a   Netter, Patrick ^a   Chary Valckenaere, Isabelle ^a,b   Loeuille, Damien ^a,b   Pourel, Jacques ^a   Grossin, Laurent ^a  

^a Biopôle de l Université de Lorraine   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; EOTAXIN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 9; LEPTIN; MESSENGER RNA; METHYLPHOSPHONIC ACID; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; TRIPLEX FORMING OLIGONUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY TRIPLEX FORMING OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BONE DESTRUCTION; CARTILAGE; CARTILAGE CELL; CHRONIC ARTHRITIS; CONTROLLED STUDY; GENE SILENCING; GENE TARGETING; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MONARTHRITIS; NONHUMAN; PROTEIN EXPRESSION; RAT; SYNOVIOCYTE; SYNOVITIS; TISSUE DISTRIBUTION;

RATTUS;

EID: 80053574435     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.156     Document Type: Article

References (46)

1. Gorman, CL and Cope, AP (2008). Immune-mediated pathways in chronic inflammatory arthritis. Best Pract Res Clin Rheumatol 22: 221-238. (Pubitemid 351606942)
2. Andreas, K, Lübke, C, Häupl, T, Dehne, T, Morawietz, L, Ringe, J et al. (2008). Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther 10: R9.
3. Manfredi, M and Benucci, M (2008). [The role of interleukin-6 in rheumatoid arthritis]. Recenti Prog Med 99: 291-294. (Pubitemid 351929877)
4. Choy, EH and Panayi, GS (2001). Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907-916. (Pubitemid 32224400)
5. Seko, Y, Cole, S, Kasprzak, W, Shapiro, BA and Ragheb, JA (2006). The role of cytokine mRNA stability in the pathogenesis of autoimmune disease. Autoimmun Rev 5: 299-305. (Pubitemid 43868196)
6. Jing, Y, Shishkov, A and Ponnappa, BC (2008). Inhibition of tumor necrosis factor secretion in rat Kupffer cells by siRNA: in vivo efficacy of siRNA-liposomes. Biochim Biophys Acta 1780: 34-40. (Pubitemid 350216951)
7. Schiffelers, RM, Xu, J, Storm, G, Woodle, MC and Scaria, PV (2005). Effects of treatment with small interfering RNA on joint inflammation in mice with collageninduced arthritis. Arthritis Rheum 52: 1314-1318. (Pubitemid 40530142)
8. Khoury, M, Escriou, V, Courties, G, Galy, A, Yao, R, Largeau, C et al. (2008). Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum 58: 2356-2367.
9. Feldmann, M, Brennan, FM, Williams, RO, Woody, JN and Maini, RN (2004). The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 18: 59-80. (Pubitemid 38324659)
10. Yoshizaki, K (2008). [Pathogenic analysis of chronic inflammatory disease based on the clinical results by IL-6 blocking therapy]. Nihon Rinsho Meneki Gakkai Kaishi 31: 104-112.
11. Bejarano, V, Quinn, M, Conaghan, PG, Reece, R, Keenan, AM, Walker, D et al.; Yorkshire Early Arthritis Register Consortium. (2008). Effect of the early use of the antitumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59: 1467-1474.
12. Hoff, M, Kvien, TK, Kälvesten, J, Elden, A and Haugeberg, G (2009). Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis 68: 1171-1176.
13. Rybar, I, Rozborilova, E, Zanova, E, Micekova, D, Solovic, I and Rovensky, J (2008). The effectiveness for prevention of tuberculosis in patients with inflammatory rheumatic diseases treated with TNF inhibitors. Bratisl Lek Listy 109: 164-167.
14. Chary-Valckenaere, I, Porumb, H, Taillandier, E and Pourel, J (1998). Oligonucleotides: a new resource in rheumatology? Rev Rhum Engl Ed 65: 543-545.
15. Mello, CC and Conte, D Jr (2004). Revealing the world of RNA interference. Nature 431: 338-342. (Pubitemid 39265673)
16. Caplen, NJ (2004). Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther 11: 1241-1248. (Pubitemid 39173430)
17. Ponnappa, BC, Israel, Y, Aini, M, Zhou, F, Russ, R, Cao, QN et al. (2005). Inhibition of tumor necrosis factor secretion and prevention of liver injury in ethanol-fed rats by antisense oligonucleotides. Biochem Pharmacol 69: 569-577. (Pubitemid 40163988)
18. Sørensen, DR, Leirdal, M and Sioud, M (2003). Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 327: 761-766. (Pubitemid 36315917)
19. Inoue, A, Takahashi, KA, Mazda, O, Terauchi, R, Arai, Y, Kishida, T et al. (2005). Electro-transfer of small interfering RNA ameliorated arthritis in rats. Biochem Biophys Res Commun 336: 903-908. (Pubitemid 41338354)
20. Felsenfeld, G and Miles, HT (1967). The physical and chemical properties of nucleic acids. Annu Rev Biochem 36: 407-448.
21. Zon, G (1988). Oligonucleotide analogues as potential chemotherapeutic agents. Pharm Res 5: 539-549.
22. Hélène, C and Toulmé, JJ (1990). Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049: 99-125.
23. Wu, Q, Gaddis, SS, MacLeod, MC, Walborg, EF, Thames, HD, DiGiovanni, J et al. (2007). High-affinity triplex-forming oligonucleotide target sequences in mammalian genomes. Mol Carcinog 46: 15-23. (Pubitemid 46095229)
24. Winters, TA (2000). Gene targeted agents: new opportunities for rational drug development. Curr Opin Mol Ther 2: 670-681. (Pubitemid 32057564)
25. Jain, A, Magistri, M, Napoli, S, Carbone, GM and Catapano, CV (2010). Mechanisms of triplex DNA-mediated inhibition of transcription initiation in cells. Biochimie 92: 317-320.
26. Vaerman, JL, Moureau, P, Deldime, F, Lewalle, P, Lammineur, C, Morschhauser, F et al. (1997). Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. Blood 90: 331-339. (Pubitemid 27276578)
27. Wickstrom, E (1986). Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 13: 97-102.
28. Akhtar, S, Kole, R and Juliano, RL (1991). Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci 49: 1793-1801.
29. Stein, CA and Krieg, AM (1994). Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 4: 67-69. (Pubitemid 24308373)
30. Miller, PS, McParland, KB, Jayaraman, K and Ts'o, PO (1981). Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 20: 1874-1880.
31. Atzeni, F and Sarzi-Puttini, P (2009). Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs 10: 1204-1211.
32. Brenner, SS, Klotz, U, Alscher, DM, Mais, A, Lauer, G, Schweer, H et al. (2004). Osteoarthritis of the knee-clinical assessments and inflammatory markers. Osteoarthr Cartil 12: 469-475. (Pubitemid 38696947)
33. Vekhoff, P, Ceccaldi, A, Polverari, D, Pylouster, J, Pisano, C and Arimondo, PB (2008). Triplex formation on DNA targets: how to choose the oligonucleotide. Biochemistry 47: 12277-12289.
34. Kohchi, C, Noguchi, K, Tanabe, Y, Mizuno, D and Soma, G (1994). Constitutive expression of TNF-and-beta genes in mouse embryo: roles of cytokines as regulator and effector on development. Int J Biochem 26: 111-119.
35. Tili, E, Michaille, JJ, Costinean, S and Croce, CM (2008). MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol 4: 534-541.
36. Pedersen, I and David, M (2008). MicroRNAs in the immune response. Cytokine 43: 391-394.
37. Hao, S and Baltimore, D (2009). The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat Immunol 10: 281-288.
38. Li, Q and Verma, IM (2002). NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734.
39. Schett, G, Stolina, M, Dwyer, D, Zack, D, Uderhardt, S, Krönke, G et al. (2009). Tumor necrosis factor and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum 60: 2644-2654.
40. Boettger, MK, Hensellek, S, Richter, F, Gajda, M, Stöckigt, R, von Banchet, GS et al. (2008). Antinociceptive effects of tumor necrosis factor neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum 58: 2368-2378.
41. Moser, B, Wolf, M, Walz, A and Loetscher, P (2004). Chemokines: multiple levels of leukocyte migration control. Trends Immunol 25: 75-84. (Pubitemid 38167488)
42. Torzilli, PA, Bhargava, M, Park, S and Chen, CT (2010). Mechanical load inhibits IL-1 induced matrix degradation in articular cartilage. Osteoarthr Cartil 18: 97-105.
43. Tanaka, T, Kuwahara, Y, Shima, Y, Hirano, T, Kawai, M, Ogawa, M et al. (2009). Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum 61: 1762-1764.
44. Toub, N, Bertrand, JR, Malvy, C, Fattal, E and Couvreur, P (2006). Antisense oligonucleotide nanocapsules efficiently inhibit EWS-Fli1 expression in a Ewing's sarcoma model. Oligonucleotides 16: 158-168.
45. Toub, N, Malvy, C, Fattal, E and Couvreur, P (2006). Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother 60: 607-620. (Pubitemid 44635092)
46. Bonhomme, F, Boucheron, C, Migliore, D and Jollès, P (1969). Arthritogenicity of unaltered and acetylated cell walls of mycobacteria. Int Arch Allergy Appl Immunol 36: 317-320.